Chemotherapy-associated hepatotoxicity in colorectal cancer

Journal of B.U.ON.

Volumn 19, Issue 2, 2014, Pages 350-356

  Cai, Zhiqiang ^a   Yang, Jiyuan ^a   Shu, Xiaoyan ^a   Xiong, Xingan ^a  

^a YANGTZE UNIVERSITY   (China)

Author keywords

Chemotherapy; Colorectal cancer; Diagnosis; Hepatotoxicity

Indexed keywords

CETUXIMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

CANCER CHEMOTHERAPY; COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; DRUG MECHANISM; HUMAN; LIVER INJURY; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; MORBIDITY; NONALCOHOLIC FATTY LIVER; REVIEW; STEATOSIS;

CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG-INDUCED LIVER INJURY; FATTY LIVER; FLUOROURACIL; HUMANS;

EID: 84904210914     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Siegel R, Naishadham D, Jemal A.Cancer statistics, 2012.CA Cancer J Clin 2012;62:10-29.
2. Leporrier J, Maurel J, Chiche L, Bara S, Segol P, Launoy G. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer.Br J Surg 2006;93:465-474.
3. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM.Epidemiology and management of liver metastases from colorectal cancer.Ann Surg 2006;244:254-259. (Pubitemid 44305540)
4. Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J.Factors influencing the natural history of colorectal liver metastases.Lancet 1994;343:1405-1410. (Pubitemid 24167517)
5. Nordlinger B, Sorbye H, Glimelius B et al.Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.Lancet 2008;371:1007-1016. (Pubitemid 351392040)
6. Adam R, Pascal G, Castaing D et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004;240:1052-1061.
7. Kopetz S, Chang GJ, Overman MJ et al.Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.J Clin Oncol 2009;27:3677-3683.
8. Chun YS, Laurent A, Maru D, Vauthey JN.Management of chemotherapy- associated hepatotoxicity in colorectal liver metastases.Lancet Oncol 2009;10:278-286.
9. Morris-Stiff G, Tan YM, Vauthey JN.Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases.Eur J Surg Oncol 2008;34:609-614. (Pubitemid 351671976)
10. Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK.Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases.Br J Surg 2007;94:274-286. (Pubitemid 46423843)
11. Kleiner DE, Brunt EM, Van Natta M et al.Design and validation of a histological scoring system for nonalcoholic fatty liver disease.Hepatology 2005;41:1313-1321. (Pubitemid 40770284)
12. Mahfud M, Breitenstein S, El-Badry AM et al.Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study.World J Surg 2010;34:92-100.
13. Mehta NN, Ravikumar R, Coldham CA et al.Effect of preoperative chemotherapy on liver resection for colorectal liver metastases.Eur J Surg Oncol 2008;34:782-786.
14. Gawrieh S, Knoedler DM, Saeian K, Wallace JR, Komorowski RA.Effects of interventions on intra- and interobserver agreement on interpretation of nonalcoholic fatty liver disease histology.Ann Diagn Pathol 2011;15:19-24.
15. El-Badry AM, Breitenstein S, Jochum W et al.Assessment of hepatic steatosis by expert pathologists: the end of a gold standard.Ann Surg 2009;250:691-697.
16. Zorzi D, Chun YS, Madoff DC, Abdalla EK, Vauthey JN.Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases.Ann Surg Oncol 2008;15:2765-2772.
17. Rubbia-Brandt L, Audard V, Sartoretti P et al.Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.Ann Oncol 2004;15:460-466. (Pubitemid 38444550)
18. Rutman RJ, Cantarow A, Paschkis KE.Studies in 2-acetylaminofluorene carcinogenesis. III. The utilization of uracil-2-C14 by preneoplastic rat liver and rat hepatoma.Cancer Res 1954;14:119-123.
19. Longley DB, Harkin DP, Johnston PG.5-fluorouracil: mechanisms of action and clinical strategies.Nat Rev Cancer 2003;3:330-338. (Pubitemid 37328853)
20. Calabro-Jones PM, Byfield JE, Ward JF, Sharp TR. Time-dose relationships for 5-fluorouracil cytotoxicity against human epithelial cancer cells in vitro. Cancer Res 1982;42:4413-4420. (Pubitemid 13205933)
21. Kufe DW, Major PP.5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity.J Biol Chem 1981;256:9802-9805. (Pubitemid 12176177)
22. Lindahl T.An N-glycosidase from Escherichia coli that releases free uracil from DNA containing deaminated cytosine residues.Proc Natl Acad Sci U S A 1974;71:3649-3653.
23. Miyake K, Hayakawa K, Nishino M, Morimoto T, Mukaihara S.Effects of oral 5-fluorouracil drugs on hepatic fat content in patients with colon cancer.Acad Radiol 2005;12:722-727. (Pubitemid 40791088)
24. Labbe G, Pessayre D, Fromenty B.Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol 2008;22:335-353.
25. Makowiec F, Möhrle S, Neeff H et al. Chemotherapy, liver injury, and postoperative complications in colorectal liver metastases.J Gastrointest Surg 2011;15:153-164.
26. Chin SN, Kim TK, Siu LL. Hepatic steatosis secondary to capecitabine: a case report. J Med Case Rep 2010;4:227.
27. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.J Clin Oncol 2001;19:4097-4106. (Pubitemid 33049527)
28. Marsh S, Hoskins JM.Irinotecan pharmacogenomics. Pharmacogenomics 2010;11:1003-1010.
29. Lavelle F, Bissery MC, André S, Roquet F, Riou JF.Pre-clinical evaluation of CPT-11 and its active metabolite SN-38.Semin Oncol 1996;23:11-20. (Pubitemid 26117267)
30. Marsh S, McLeod HL. Pharmacogenetics of irinotecan toxicity. Pharmacogenomics 2004;5:835-843. (Pubitemid 39386752)
31. Vauthey JN, Pawlik TM. Ribero D et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases.J Clin Oncol 2006;24:2065-2072.
32. Begriche K, Igoudjil A, Pessayre D, Fromenty B.Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it.Mitochondrion 2006;6:1-28.
33. Zhang H, Barceló JM, Lee B et al. Human mitochondrial topoisomerase I.Proc Natl Acad Sci U S A 2001;98:10608-10613. (Pubitemid 32878668)
34. Kosovsky MJ, Soslau G.Mitochondrial DNA topoisomerase I from human platelets.Biochim Biophys Acta 1991;1078:56-62.
35. Kosovsky MJ, Soslau G.Immunological identification of human platelet mitochondrial DNA topoisomerase I.Biochim Biophys Acta 1993;1164:101-107. (Pubitemid 23186295)
36. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E.Cellular and molecular pharmacology of oxaliplatin.Mol Cancer Them 2002;1:227-235.
37. Woynarowski JM, Chapman WG, Napier C, Herzig MC, Juniewicz P.Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA.Mol Pharmacol 1998;54:770-777. (Pubitemid 28523169)
38. Rubbia-Brandt L, Lauwers GY, Wang H et al.Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 2010;56:430-439.
39. Cassidy J. Current role of biological agents in colorectal cancer. J Hong Kong Coll Radiol 2010;13:S3-9.
40. Van Cutsem E, Köhne CH, Lang I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.J Clin Oncol 2011;29:2011-2019.
41. Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.N Engl J Med 2009;360:1408-1417.
42. Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E.Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012;30:3570-3577.
43. Pessaux P, Panaro F, Casnedi S et al.Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study.Eur J Surg Oncol 2010;36:575-582.
44. Bokemeyer C, Van Cutsem E, Rougier P et al.Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.Eur J Cancer 2012;48:1466-1475.
45. Robinson SM, Wilson CH, Burt AD, Manas DM, White SA.Chemotherapy- associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol 2012;19:4287-4299.
46. Overman MJ, Maru DM, Charnsangavej C et al.Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury.J Clin Oncol 2010;28:2549-2555.
47. Starkey Lewis PJ, Dear J, Platt V et al.Circulating microRNAs as potential markers of human drug-induced liver injury.Hepatology 2011;54:1767-1776.
48. Yang X, Greenhaw J, Shi Q et al.Identification of urinary microRNA profiles in rats that may diagnose hepatotoxicity. Toxicol Sci 2012;125:335-344.